Roche-Spark deal faces FTC Republicans who overruled Democrats on BMS-Celgene
Roche’s acquisition of Spark Therapeutics is pending before a Federal Trade Commission that was starkly divided along party lines in a recent pharma deal that the Republican majority was willing to...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch